Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAP2 | P11137 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87871 | 0.87 | KDM4E (0.65) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL2339411 | 0.86 | KDM4E (0.66) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL29955046 | 0.86 | KDM4E (0.66) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL10704376 | 0.81 | ALDH1A1 (0.61) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL3275504 | 0.81 | MEN1 (0.65) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL9654119 | 0.81 | KDM4E (0.57) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL29950909 | 0.79 | KDM4E (1.00) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL30373749 | 0.78 | KDM4E (0.53) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL570154 | 0.78 | NR4A2 (0.67) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL5568381 | 0.78 | KDM4E (0.53) | KDM4EMEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3456718-B1 | ISATIN-DERIVED COMPOUNDS, USE OF THE COMPOUNDS FOR THE TREATMENT OF AIDS AND HBV INFECTIONS | FUNDACAO OSWALDO CRUZ (BR) | 2021-02-17 | — | — | EP | disclosed |
| US-20190177305-A1 | ISATIN-DERIVED COMPOUNDS, USE OF THE COMPOUNDS FOR THE TREATMENT OF AIDS AND METHOD OF TREATMENT USING THESE COMPOUNDS | FUNDAÇÃO OSWALDO CRUZ (BR) | 2019-06-13 | — | — | US | disclosed |
| EP-3456718-A1 | ISATIN-DERIVED COMPOUNDS, USE OF THE COMPOUNDS FOR THE TREATMENT OF AIDS AND METHOD OF TREATMENT USING THESE COMPOUNDS | Fundação Oswaldo Cruz (fiocruz) - Superintendência De Planejamento (BR) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017193180-A1 | ISATIN-DERIVED COMPOUNDS, USE OF THE COMPOUNDS FOR THE TREATMENT OF AIDS AND METHOD OF TREATMENT USING THESE COMPOUNDS | FUNDAÇÃO OSWALDO CRUZ (FIOCRUZ) - SUPERINTENDÊNCIA DE PLANEJAMENTO (BR) | 2017-11-16 | — | — | WO | disclosed |
| US-8946283-B2 | Composition for preventing or treating obesity, dyslipidemia, fatty liver or diabetes containing indole-3-carbinol derivative as active ingredient | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2015-02-03 | — | — | US | disclosed |
| US-8946283-B2 | Composition for preventing or treating obesity, dyslipidemia, fatty liver or diabetes containing indole-3-carbinol derivative as active ingredient | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2015-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177305-A1 | ISATIN-DERIVED COMPOUNDS, USE OF THE COMPOUNDS FOR THE TREATMENT OF AIDS AND METHOD OF TREATMENT USING THESE COMPOUNDS | IMPDH1, HASPIN, IMPDH2 | KDM4E 4051/4885TDP1 4158/4885MEN1 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.